Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate
| Autor: | Daniel Kantor, Hall Steven E, Sanjeev Balu, Michael Grabner, Benjamin Greenberg, Xian Zhang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Recurrence Health care Humans Medicine 030212 general & internal medicine Glatiramer acetate Intensive care medicine Retrospective Studies business.industry Multiple sclerosis Glatiramer Acetate Health Care Costs General Medicine Middle Aged medicine.disease Managed care Female business medicine.drug |
| DOI: | 10.6084/m9.figshare.12189540.v1 |
| Popis: | Objective: To compare relapse rates and healthcare costs in MS patients treated with Glatopa 20 mg (generic glatiramer acetate) versus Copaxone 20 mg in a US managed care population. Methods: A retrospective claims study was conducted using the HealthCore Integrated Research Database. Patients with ≥1 Glatopa or Copaxone claim between 01 April 2015 (Glatopa) or 01 January 2013 (Copaxone) and 30 April 2018 were included. Patients with prior Copaxone 40 mg use or Results: A total of 357 Glatopa and 2291 Copaxone patients qualified for inclusion; 158 per cohort were retained after matching. Baseline characteristics were well-balanced (mean age 49.9 years, 75% female, mean 3.8 Copaxone fills). At baseline, 8% of patients had ≥1 relapse with mean annualized relapse rates (ARR) of 0.18; at follow-up, the relapse rates were 8% versus 15% (Glatopa versus Copaxone; p = .05), and ARRs were 0.12 versus 0.30 (p = .05). 45% of Glatopa patients switched (back) to Copaxone 20/40 mg and were censored at that point. Mean (SD) all-cause medical and pharmacy costs were $51,507 ($28,494) versus $55,085 ($37,061; p = .50). Mean MS-related costs were $45,379 ($24,732) versus $47,949 ($32,615; p = .67), of which mean disease modifying therapy costs were $42,926 ($23,196) versus $44,932 ($28,554; p = .59). Results were similar in sensitivity analyses. Conclusions: In this real-world study, MS patients treated with Glatopa experienced similar health outcomes and costs compared to those treated with Copaxone, with a trend towards lower relapse rates (borderline statistically significant) and cost savings (not statistically significant). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|